Innogenetics changes name to Fujirebio Europe

Miraca Holdings Inc., a Japan-based holding company in the healthcare sector, recently announced that its affiliate Innogenetics N.V. in Ghent (Belgium) had changed its name to Fujirebio Europe N.V. The name change is the next logical step in an integration process that was launched by the acquisition in September 2010 of Innogenetics N.V. by Fujirebio Inc., a subsidiary of Miraca Holdings. Fujirebio is recognized as a key player in oncology for routine and novel IVD markers. Th e name change confirms Fujirebio’s strong commitment to the introduction of the Lumipulse immunoanalyser range in laboratories across Europe. The Lumipulse G1200 was presented to the European market for the first time in Italy in November 2011 and this fully automated chemiluminescent enzyme immunoassay (CLEIA) system is now available to laboratories in Spain and will soon be available in Germany and France.

www.fujirebio-europe.com